Holen Sie sich die Stockscreener-App
47.08
1.30%
-0.62
Handel nachbörslich:
47.50
0.42
+0.89%
Praxis Precision Medicines Inc Aktie (PRAX) Neueste Nachrichten
Bronstein, Gewirtz & Grossman, LLC Encourages Praxis Precision Medicines, Inc. (PRAX) Investors to Inquire about Securities Investigation - ACCESS Newswire
Published on: 2025-08-15 03:59:03 - Newser
What indicators show strength in Praxis Precision Medicines Inc.July 2025 Update & Community Supported Trade Ideas - Newser
Lost Money on Praxis Precision Medicines, Inc. (PRAX)? Possible FraudContact Levi & Korsinsky Today - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Praxis Precision Medicines, Inc. (PRAX) And Encourages Investors to Reach Out - ACCESS Newswire
Praxis Precision Medicines shares fall 1.89% intraday after Schall Law Firm investigates claims of false statements. - AInvest
Levi & Korsinsky Investigates Possible Securities Fraud by Praxis Precision Medicines, Inc. (PRAX) - ACCESS Newswire
PRAX Investors Have Opportunity to Join Praxis Precision Medicines, Inc. Fraud Investigation with the Schall Law Firm - Barchart.com
Will Praxis Precision Medicines Inc. bounce back from current supportGap Up & Safe Capital Allocation Plans - Newser
Does Praxis Precision Medicines Inc. stock pay reliable dividends2025 Buyback Activity & Precise Buy Zone Tips - Newser
Levi & Korsinsky Investigating Whether Praxis Precision Medicines, Inc. (PRAX) Misled InvestorsSecurities Law Violations Possible - ACCESS Newswire
Advanced analytics toolkit walkthrough for Praxis Precision Medicines Inc.2025 Winners & Losers & High Win Rate Trade Tips - Newser
What are the future prospects of Praxis Precision Medicines Inc.Volume Surge With Low Float - thegnnews.com
Will Praxis Precision Medicines Inc. see short term momentumRisk-Managed Trade Alerts for Consistency - Newser
Investigation Alert: Levi & Korsinsky Investigates Securities Fraud Claims Against Praxis Precision Medicines, Inc. (PRAX) - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Praxis Precision Medicines, Inc.PRAX - PR Newswire
Piper Sandler reiterates Overweight rating on Praxis Precision Medicines stock - Investing.com Nigeria
Chardan Capital Brokers Lower Earnings Estimates for PRAX - Defense World
Why Praxis Precision Medicines Inc. stock attracts strong analyst attentionRisk-Managed Trade Alerts for Consistency - Newser
ATTENTION PRAX Shareholders: Lost Money on Praxis Precision Medicines, Inc.? Contact Levi & Korsinsky About Investigation - ACCESS Newswire
Praxis Precision Medicines (PRAX) to Release Quarterly Earnings on Tuesday - Defense World
Praxis Precision Medicines Q2 results disappoint, stock falls 5.55% - AInvest
Is Praxis Precision Medicines Inc. stock reversal real or fakeSecure Trading Strategy Based on Technical Analysis - Newser
Is Praxis Precision Medicines Inc. meeting your algorithmic filter criteriaReal Market Tracker with Price Action Tools - Newser
Reversal indicators forming on Praxis Precision Medicines Inc. stockFree Weekly Potential Breakout Stock List - Newser
What is HC Wainwright’s Forecast for PRAX Q3 Earnings? - Defense World
HC Wainwright Reiterates “Buy” Rating for Praxis Precision Medicines (NASDAQ:PRAX) - Defense World
Praxis Precision Medicines’ Positive Earnings Call Highlights Vormatrigine Success - MSN
Praxis Precision Medicines: Marcio Firm's Insights - AInvest
What is Wedbush’s Forecast for PRAX Q3 Earnings? - Defense World
FY2029 Earnings Forecast for PRAX Issued By HC Wainwright - Defense World
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Praxis Precision Medicines Grants 3,875 Restricted Stock Units to Strategic New Hires - Stock Titan
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Q2 2025 Earnings Call Transcript - Insider Monkey
Will Praxis Precision Medicines Inc. stock split in the near futureDaily Pattern Analysis with Return Forecast - Newser
Praxis Precision Medicines Advances Epilepsy Treatment with Promising Study Results and Strong Financial Positioning - AInvest
Praxis Precision Medicines: A Dual-Platform Innovator Capturing the Future of Precision Neurology - AInvest
Praxis Precision Medicines to Participate in Upcoming Fireside C - GuruFocus
Praxis Precision Medicines to Participate in Upcoming Fireside Chat - GlobeNewswire
Praxis Precision Medicines, Inc. Investors: Company Investigated by the Portnoy Law Firm - GlobeNewswire
Praxis Precision Medicines stock holds Buy rating at Truist on seizure reduction data - Investing.com India
Praxis Precision Medicines stock holds Buy rating at Truist on seizure reduction data By Investing.com - Investing.com South Africa
A Quick Look at Today's Ratings for Praxis Precision Medicines(PRAX.US), With a Forecast Between $33 to $155 - 富途牛牛
Praxis Precision Medicines First Half 2025 Earnings: US$6.60 loss per share (vs US$4.58 loss in 1H 2024) - Yahoo Finance
Praxis’ vormatrigine eliminates seizures in 22% of patients in Phase II trial - Yahoo Finance
Praxis Precision Medicines Inc (PRAX) Q2 2025 Earnings Call Highlights: Vormatrigine Shows ... - Yahoo Finance
Praxis Precision Medicines Inc (PRAX) Q2 2025 Earnings Call Highlights: Vormatrigine Shows ... By GuruFocus - Investing.com Canada
Praxis Precision Medicines Reports Promising Study Results - TipRanks
Decoding Praxis Precision Medicines Inc (PRAX): A Strategic SWOT Insight - GuruFocus
Praxis Precision Medicines to Participate in Virtual Fireside Chat Hosted by Truist Securities - AInvest
Praxis Precision Medicines to Participate in Upcoming Fireside Chat | PRAX Stock News - GuruFocus
Praxis Precision Medicines Shares Surge on Promising Epilepsy Drug Data - MSN
Guggenheim raises Praxis Precision Medicines stock price target on positive seizure drug data - Investing.com Australia
Praxis Precision Medicines stock holds Buy rating at TD Cowen on promising seizure data - Investing.com Canada
Praxis: Positive 8-Week Radiant Study Data Leads To Other Expected Catalysts - Seeking Alpha
Praxis Precision Medicines stock price target raised by Wedbush to $33 - Investing.com South Africa
0.41%
0.88%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):